English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aims . To determine whether the erythrocyte phosphorylated ribavirin (RBV) level might be a useful index of EVR and risk of anemia and to determine the optimal dose of RBV in 24 patients with hepatitis C with pegylated interferon and RBV.  Methodology . The RBV level was measured by a high-performance liquid chromatography.  Results and Conclusion . In patients aged 50 years or over, a negative correlation ( r  = −0.548,  P  < .05) was observed between the RBV level at week 2 and rate of Hb reduction (ΔHb) at week 4. The ΔHb at week 4 was significantly greater in patients with RBV levels of ≥800  μ M (−25.5 ± 10.1%) than in patients with RBV levels <800  μ M (−15.6 ± 7.7%). None of the patients with RBV levels <600  μ M at week 2 achieved EVR and SVR. Thus the optimal levels of erythrocyte phosphorylated RBV at week 2 of therapy in order to achieve EVR without anemia seemed to be 600–800  μ M.

hepatitis research and treatment

Optimal Erythrocyte Ribavirin Level to Reduce the Risk of Anemia and Obtain an Early Virological Response in Patients with Chronic Hepatitis C Caused by Genotype 1b Infection